Cure My Disease

Don't miss your cure!

 Log in / Sign up

German hospitals pool infection data and samples to speed future research

NCT ID NCT06879184

Knowledge-focused Sponsor: Goethe University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 29, 2026 · Last updated Sep 30, 2026 · Updated 1 time

Summary

Researchers at university hospitals across Germany are building a large observational cohort of adults and children hospitalized with infections. The study collects standardized clinical data, pathogen samples, and biosamples at the start and end of each hospital stay. A pre-screening program tracks infection-related admissions to help detect pathogen changes early. The goal is to create a shared resource that other scientists can use to study disease severity, spread, and outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If the cohort succeeds, researchers could gain a shared resource for studying how infections spread, how severe they become, and which treatments work. It may also help hospitals spot new pathogen trends earlier.
What could go wrong
This is an observational study, so it does not test a treatment and cannot prove that any care approach works. The value depends on recruiting enough participants, collecting samples consistently, and whether future researchers can use the data effectively.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 15,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

Jun 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with defined clinical characteristics or presentations/pathogens are included at all participating study sites. Specific clinical characteristics or presentations/pathogens of interest are defined in the specific modules. Based on this master study protocol and the modules, the study teams will identify patients who meet all inclusion and none of the exclusion criteria and will inform them about the study and its objectives. Patients providing written IC will be included in the study.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Fulfillment of all inclusion and no exclusion criteria for at least one module * Ability to perform all baseline visit data and biosample collections according to the study requirements no later than 48 hours (with an additional 48-hour period for weekends) after fulfilling all study and specific module inclusion and exclusion criteria * Signed informed consent form from all patients capable of giving consent and understanding all contents of the informed consent * Age ≥ 18 years. Exclusion Criteria: There are no generic exclusion criteria in the master study protocol.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Infectious diseases and manifestations are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Infectious diseases and manifestations

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University Hospital Frankfurt

    RECRUITING

    Frankfurt, 60590, Germany